CENCORA, INC. (COR) FY2026 Q2 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2026-01-01 to 2026-03-31

Swipe to see the full flow
CENCORA, INC. cash flow reconciliation, Jan 1, 2026 through Mar 31, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Calculated remaining financing cash flows are purple; remaining operating and investing bundles are gray. Their underlying inflows and outflows are not separately identified. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net income → Net cash from operating activities: $1,338,639,000.00Net income → Operating adjustments reconciliation: $290,889,000.00Inventories → Operating adjustments reconciliation: $3,399,637,000.00Accounts receivable → Operating adjustments reconciliation: $522,077,000.00Provision for deferred income taxes → Operating adjustments reconciliation: $178,407,000.00Depreciation, including amounts charged to cost of goods sold → Operating adjustments reconciliation: $142,302,000.00Amortization, including amounts charged to interest expense → Operating adjustments reconciliation: $120,675,000.00Accrued expenses → Operating adjustments reconciliation: $70,971,000.00Prepaid expenses and other assets → Operating adjustments reconciliation: $68,490,000.00Adjustments to RCA and OneOncology equity units → Operating adjustments reconciliation: $55,445,000.00Share-based compensation expense → Operating adjustments reconciliation: $28,002,000.00Türkiye highly inflationary impact → Operating adjustments reconciliation: $10,474,000.00Operating adjustments reconciliation → Accounts payable: $3,501,753,000.00Operating adjustments reconciliation → Remeasurement gain related to OneOncology acquisition (Note 2): $1,086,612,000.00Operating adjustments reconciliation → LIFO (credit) expense: $210,030,000.00Operating adjustments reconciliation → Income taxes payable and other liabilities: $78,174,000.00Operating adjustments reconciliation → Other, net: $5,681,000.00Operating adjustments reconciliation → (Benefit) provision for credit losses: $4,885,000.00Operating adjustments reconciliation → Gain on sale of assets: $234,000.00Borrowings under revolving and securitization credit facilities → financing reconciliation: $47,212,956,000.00Senior notes and loan borrowings → financing reconciliation: $4,540,483,000.00financing reconciliation → Net cash from financing activities: $3,978,567,000.00financing reconciliation → Repayments under revolving and securitization credit facilities: $47,424,106,000.00financing reconciliation → Senior notes and loan repayments: $217,784,000.00financing reconciliation → Cash dividends on common stock: $117,456,000.00financing reconciliation → Remaining financing cash flows, net (calculated): $7,598,000.00financing reconciliation → Employee tax withholdings related to restricted share vesting: $7,035,000.00financing reconciliation → Other, net: $893,000.00Net cash used in investing activities → investing reconciliation: $4,874,901,000.00Non-customer note receivable → investing reconciliation: $20,626,000.00Proceeds from sale of assets → investing reconciliation: $717,000.00investing reconciliation → Cost of acquired companies, net of cash acquired: $4,712,350,000.00investing reconciliation → Capital expenditures: $165,618,000.00investing reconciliation → Other, net: $9,776,000.00investing reconciliation → Cost of equity investments: $8,500,000.00Exchange-rate effect → Cash sources and uses: $24,576,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $1,808,693,000.00Net cash from operating activities → Cash sources and uses: $1,338,639,000.00Net cash from financing activities → Cash sources and uses: $3,978,567,000.00Cash sources and uses → Other changes in cash (calculated): $39,312,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $2,236,262,000.00Cash sources and uses → Net cash used in investing activities: $4,874,901,000.00Income taxes payable and other liabilities: -$78,174,000.00Income taxes payable & other−$78.17 MLoss on divestiture of businesses: $0.00Net income: $1,629,528,000.00Net income+$1.63 BAmortization, including amounts charged to interest expense: $120,675,000.00Amortization expense+$120.68 MPrepaid expenses and other assets: $68,490,000.00Prepaid & other assets+$68.49 M(Benefit) provision for credit losses: -$4,885,000.00Credit loss provision−$4.89 MDepreciation, including amounts charged to cost of goods sold: $142,302,000.00Depreciation expense+$142.30 MAccounts receivable: $522,077,000.00Accounts receivable+$522.08 MProvision for deferred income taxes: $178,407,000.00Deferred income taxes+$178.41 MOther, net: -$5,681,000.00Other non-cash items−$5.68 MShare-based compensation expense: $28,002,000.00Stock-based compensation+$28.00 MAdjustments to RCA and OneOncology equity units: $55,445,000.00Contingent consideration change+$55.45 MTürkiye highly inflationary impact: $10,474,000.00Türkiye inflationary impact+$10.47 MLIFO (credit) expense: -$210,030,000.00Inventory reserve provision−$210.03 MAccounts payable: -$3,501,753,000.00Accounts payable−$3.50 BGain on remeasurement of equity investment: $0.00Inventories: $3,399,637,000.00Inventories+$3.40 BAccrued expenses: $70,971,000.00Accrued liabilities+$70.97 MImpairment of assets, including goodwill: $0.00Gain on sale of assets: -$234,000.00Other asset gain & loss−$234.00 KRemeasurement gain related to OneOncology acquisition (Note 2): -$1,086,612,000.00Stake remeasurement gain & loss−$1.09 BNet cash from operating activities: $1,338,639,000.00Operating cash+$1.34 BOperating adjustments reconciliation: $4,887,369,000.00Senior notes and loan repayments: -$217,784,000.00Long-term debt repaid−$217.78 MSenior notes and loan borrowings: $4,540,483,000.00Debt issued+$4.54 BBorrowings under revolving and securitization credit facilities: $47,212,956,000.00Credit line borrowings+$47.21 BCash dividends on common stock: -$117,456,000.00Common dividends paid−$117.46 MRepayments under revolving and securitization credit facilities: -$47,424,106,000.00Credit line repayments−$47.42 BOther, net: -$893,000.00Other financing, net−$893.00 KEmployee tax withholdings related to restricted share vesting: -$7,035,000.00Stock-award tax withholding−$7.04 MPurchases of common stock: -$0.00Remaining financing cash flows, net (calculated): -$7,598,000.00Remaining financing (calculated)−$7.60 MNet cash from financing activities: $3,978,567,000.00Financing cash+$3.98 Bfinancing reconciliation: $51,753,439,000.00Capital expenditures: -$165,618,000.00PP&E purchases−$165.62 MCost of acquired companies, net of cash acquired: -$4,712,350,000.00Acquisitions, net of cash−$4.71 BOther, net: -$9,776,000.00Other investing, net−$9.78 MNon-customer note receivable: $20,626,000.00Non-customer note receivable+$20.63 MCost of equity investments: -$8,500,000.00Equity-method investments made−$8.50 MProceeds from sale of assets: $717,000.00Other asset sales+$717.00 KNet cash used in investing activities: -$4,874,901,000.00. Cash required to fund net payments.Investing cash−$4.87 Binvesting reconciliation: $4,896,244,000.00Cash sources and uses: $7,150,475,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $1,808,693,000.00Beginning cash$1.81 BEnding cash: Cash, cash equivalents, and restricted cash: $2,236,262,000.00Ending cash$2.24 BExchange-rate effect: $24,576,000.00FX effect+$24.58 MOther changes in cash (calculated): -$39,312,000.00Other changes in cash(calculated)−$39.31 MCASH RECONCILIATIONOperatingflowsFinancingflowsInvestingflowsFree cash flow$1.17 BOperating cash − cash spent on PP&ECash flow / Net income0.82×Operating cash flow ÷ net incomeNet cash change+$427.57 MEnding cash − beginning cash
Chart details

CENCORA, INC. cash flow reconciliation, Jan 1, 2026 through Mar 31, 2026

Cash flows for Jan 1, 2026 through Mar 31, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Mar 31, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
1,808,693,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
1,338,639,000 US dollars. Net cash provided.
Income taxes payable and other liabilities
negative 78,174,000 US dollars
Loss on divestiture of businesses
0 US dollars
Net income
1,629,528,000 US dollars
Amortization, including amounts charged to interest expense
120,675,000 US dollars
Prepaid expenses and other assets
68,490,000 US dollars
(Benefit) provision for credit losses
negative 4,885,000 US dollars
Depreciation, including amounts charged to cost of goods sold
142,302,000 US dollars
Accounts receivable
522,077,000 US dollars
Provision for deferred income taxes
178,407,000 US dollars
Other, net
negative 5,681,000 US dollars
Share-based compensation expense
28,002,000 US dollars
Adjustments to RCA and OneOncology equity units
55,445,000 US dollars
Türkiye highly inflationary impact
10,474,000 US dollars
LIFO (credit) expense
negative 210,030,000 US dollars
Accounts payable
negative 3,501,753,000 US dollars
Gain on remeasurement of equity investment
0 US dollars
Inventories
3,399,637,000 US dollars
Accrued expenses
70,971,000 US dollars
Impairment of assets, including goodwill
0 US dollars
Gain on sale of assets
negative 234,000 US dollars
Remeasurement gain related to OneOncology acquisition (Note 2)
negative 1,086,612,000 US dollars
Investing activities
negative 4,874,901,000 US dollars. Net cash used.
Capital expenditures
negative 165,618,000 US dollars
Cost of acquired companies, net of cash acquired
negative 4,712,350,000 US dollars
Other, net
negative 9,776,000 US dollars
Non-customer note receivable
20,626,000 US dollars
Cost of equity investments
negative 8,500,000 US dollars
Proceeds from sale of assets
717,000 US dollars
Financing activities
3,978,567,000 US dollars. Net cash provided. The remaining amount is calculated by subtracting the other displayed items from the financing total. This quarter is the year to date less the prior quarter's year to date. The prior quarter reported part of this section under different lines (Exercises of stock options), so those amounts cannot be separated for this quarter. It may combine inflows and outflows.
Senior notes and loan repayments
negative 217,784,000 US dollars
Senior notes and loan borrowings
4,540,483,000 US dollars
Borrowings under revolving and securitization credit facilities
47,212,956,000 US dollars
Cash dividends on common stock
negative 117,456,000 US dollars
Repayments under revolving and securitization credit facilities
negative 47,424,106,000 US dollars
Other, net
negative 893,000 US dollars
Employee tax withholdings related to restricted share vesting
negative 7,035,000 US dollars
Purchases of common stock
0 US dollars
Remaining financing cash flows, net (calculated)
negative 7,598,000 US dollars
Operating adjustment reconciliation
4,887,369,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing displayed reconciliation
51,753,439,000 US dollars. Intermediate calculation joining the displayed items and the calculated net remainder. It does not establish gross cash receipts or payments and is not an additional cash flow.
investing gross reconciliation
4,896,244,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
24,576,000 US dollars
Other changes in cash (calculated)
negative 39,312,000 US dollars. Out of cash; drawn as the small gray flow above ending cash.
Ending cash on Mar 31, 2026
2,236,262,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
7,150,475,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
427,569,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
0.82×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
1,338,639,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
165,618,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
1,173,021,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income exceeds operating cash. The diagram allocates $1.34B of net income directly to operating cash and $290.89M to the adjustment junction, where it combines with other additions to reconcile deductions. This is an accounting presentation, not a tracing of cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 1,338,639,000 US dollars minus 165,618,000 US dollars equals 1,173,021,000 US dollars.
CENCORA, INC. (COR) FY2026 Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!